Azilect (rasagiline) slows the progression of Parkinson’s disease.
January 1
This has been a burning question with MAO-B inhibitors for years...first with selegiline and now with Azilect.
Azilect gives us a glimmer of hope...because a single industry-sponsored study suggests that 1 mg/day might slow disease progression.
But that same study shows that 2 mg/day doesn’t help. This has many experts questioning whether 1 mg/day really works...because it doesn’t make sense that a higher dose wouldn’t work when a lower dose does.
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber Insights: APRN includes:
- Cutting-edge advice about new medications and how they fit into practice
- Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
- Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations
Already a subscriber? Log in
Volume pricing available. Get a quote